MedTrace Logo

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

NCT00526968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2008-02-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.

Conditions

  • Human Volunteers

Interventions

DRUG

EVT 101

8 mg capsule, single oral dose

DRUG

EVT 101

15 mg capsule, single oral dose

DRUG

placebo

Placebo capsule, single oral dose

Sponsors & Collaborators

  • Richmond Pharmacology Limited

    collaborator INDUSTRY

  • Evotec Neurosciences GmbH

    lead INDUSTRY

Principal Investigators

  • Nigel Leigh, BSc MBBS Phd · Department of Clinical Neurosciences, Institute of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00526968 on ClinicalTrials.gov